← Eichor
Study identifier: NCT06355713 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Improvement of Symptoms After Removal of the Essure® Contraceptive Implant

Condition: Implant Complication · Contraceptive Device; Complications  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants444
Who can joinFemale, 35 Years to 75 Years
Healthy volunteersNo

About this study

ESSURE® is an implantable medical device for definitive and irreversible sterilization indicated for adult women of childbearing age. These implants are inserted into the fallopian tubes by hysteroscopy. Marketed in 2002, ESSURE® contraceptive implants were withdrawn from the French market in 2017 (and worldwide in 2017 and 2018) following the observation in certain patients of polymorphic and non-specific gynecological and extra-gynecological symptoms. Studies with small numbers and short-term follow-up have shown a significant improvement in these symptoms after implant explantation. This constitutes a real public health problem since according to the report of the EPI-PHARE Scientific Interest Group, 198,000 French women have these implants and only 30,000 of them, or 15%, have been explanted, knowing that explantation of ESSURE® implants is recommended only in symptomatic patients. A large number of these patients, presenting symptoms, have not yet been treated for an explant. The physiopathological mechanism(s) is (are) not yet determined but several arguments are in favor of a dissemination of metallic elements contained in these implants whose accumulation could lead to inflammatory and/or allergic and/or autoimmune phenomena. Carrying out a prospective study with long-term longitudinal follow-up appears essential to precisely assess the degree of improvement in the symptoms and quality of life of these patients, determine the most appropriate surgical techniques, an…

This description comes directly from the study's public registry record.

Talk to the study team

Gautier Chene, PU,PH  ·  0472355870  ·  gautier.chene@chu-lyon.fr

Stéphanie MORET  ·  0472355878  ·  stephanie.moret@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (10)

CHU de AngersAngers, FranceNot Yet Recruiting
Hôpital Femme Mère Enfant (Hospices Civils de Lyon)Bron, FranceRecruiting
Hôpital BicêtreLe Kremlin-Bicêtre, FranceNot Yet Recruiting
Hôpital Jeanne de FlandresLille, FranceNot Yet Recruiting
Hôpital de La ConceptionMarseille, FranceNot Yet Recruiting
Institut Mère Enfant Alix de Champagne, CHU ReimsReims, FranceNot Yet Recruiting
CHU de RouenRouen, FranceNot Yet Recruiting
Hôpital de Hautepierre, Hôpitaux Universitaires de StrasbourgStrasbourg, FranceNot Yet Recruiting
Hôpital Paule de Viguier, CHU de ToulouseToulouse, FranceNot Yet Recruiting
Hôpital André Mignot, Centre Hospitalier de VersaillesVersailles, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06355713